On the stock market since 2013, it operates in the world of health and science. It has 225 employees. Now — the numbers.
The stock trades 17% below its peak. The market has trimmed its expectations for the company.
It pays out $0.22 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, KARBF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KARBF is a high-risk stock — not yet profitable, and its future rides on its product catching on.